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Abstract 
Inflammation is a shared mechanism in coronary artery disease (CAD) and subsequent heart failure (HF) 
and circulating monocyte and lymphocyte counts predict CAD severity and outcomes. We investigated 
whether the monocyte-to-lymphocyte ratio (MLR) correlates with biomarkers of HF and extent of CAD, as 
well as future HF hospitalizations in patients undergoing coronary angiography (CAG). Therefore, we 
studied 1754 patients undergoing CAG for stable CAD, unstable angina or myocardial infarction (MI). 
MLR was determined at blood draw prior to angiography and related cross-sectionally to HF biomarkers 
(ejection fraction [EF], N-terminal pro-B-type natriuretic peptide [NTproBNP] levels) and CAD severity, 
as well as longitudinally with risk of HF hospitalizations during follow-up. In the entire cohort, median 
(interquartile range) MLR was 0.32 (0.24-0.43). High MLR was defined as the upper quartile and 
significantly associated with non-stable CAD (unstable angina [Odds ratio=1.13; 95% confidence interval 
1.06-1.21] or MI [OR=1.10; 1.04-1.16]), more severe CAD (OR=1.39; 1.15-1.68), poorer EF (OR=1.63; 
1.29-2.05) and higher NTproBNP levels (β=0.78; 0.59-0.96), all p<0.001. The associations with non-stable 
CAD and NTproBNP remained highly significant after covariate adjustment. Over a mean follow-up of 1.3 
years, 46 HF hospitalizations occurred. A high MLR was significantly and independently predictive of HF 
hospitalizations during follow-up (HR 2.1 [1.1-4.1], p=0.039) after adjustment for covariates and addition 
of MLR to the basic model significantly improved reclassification. In conclusion, MLR is strongly related 
to HF markers and predicts HF hospitalizations during follow-up in CAD patients. 
 
Key words: heart failure (HF); coronary artery disease (CAD); monocyte-to-lymphocyte ratio (MLR); 
lymphocyte-to-monocyte ratio (LMR); inflammation
 3 
Introduction 
The role of inflammation and inflammatory cells in cardiovascular disease has been demonstrated in 
countless studies, showing that leukocyte1, monocyte2, neutrophil counts3 and ratios hereof4 are related 
to coronary artery disease (CAD) severity and outcome. The monocyte-to-lymphocyte ratio (MLR) 
has recently been introduced as a potent predictor of mortality among coronary angiography (CAG) 
patients.5,6 In addition to its role in coronary atherosclerosis, inflammation is also involved in the 
pathogenesis of heart failure (HF). Although a number of studies have investigated clinical factors7 
and imaging modalities8, evidence for the predictive capacity of circulating inflammatory cells in HF 
prediction is lacking. Given the close relation of higher monocyte levels and lower lymphocyte levels5 
with myocardial injury and subsequent HF, and the strong association of MLR with (cardiovascular5) 
mortality6, we investigated the relation of MLR to HF biomarkers and HF hospitalizations during 
follow-up among patients with varying degrees of CAD.  
 
Methods 
 In this study, we included CAG patients from the Utrecht Coronary Biobank (UCORBIO) 
cohort9 with available MLR (1754/1845 patients). Indications for CAG were stable CAD (complaints 
of dyspnea or chest pain upon exertion and >50% stenosis in one of the coronary arteries), unstable 
angina or MI. Patients undergoing CAG for other indications were excluded from the current analyses. 
The medical ethics committee of the UMCU approved the study and all patients provided written 
informed consent. UCORBIO is registered under the clinicaltrials.gov ID: NCT02304744. The study 
conforms to the Declaration of Helsinki. 
 Clinical data were collected as described previously.10 In brief, demographic data, history of 
acute coronary syndrome (ACS), percutaneous coronary intervention (PCI), coronary artery bypass 
grafting (CABG), cerebrovascular accident/transient ischemic attack (CVA/TIA) and peripheral 
arterial disease (PAD), medication use, cardiovascular risk factors: diabetes mellitus, body mass index 
(BMI), hypertension, hypercholesterolemia, smoking and the indication for CAG, the angiographic 
severity of CAD and procedural details were collected at the moment of enrollment. 
 Echocardiographic EF was grouped into 4 categories: <30%, 30-39%, 40-49% and >50%.  
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An arterial blood sample was drawn from the arterial sheath inserted for CAG before any procedure-
related drugs were administered. Differential blood counts were performed in accordance with routine 
clinical practice using the Abbott Cell-Dyn hematology analyzer. All hematological parameters were 
subsequently stored in and extracted from the Utrecht Patient-Oriented Database (UPOD).11  
 Patients are followed-up for 5 years, of which 3 years had passed at the moment of writing. 
Every year, patients received a questionnaire to ask for hospital hospitalizations for any reason. When 
patients reported a potential event or when the patient did not return the questionnaire, the general 
practitioner or the said hospital was contacted for confirmation of the hospitalization. In case of 
hospitalization, medical records were requested and a panel of cardiologists adjudicated the event.  
 All analyses were performed on data with imputed covariates in order to avoid bias caused by 
data missing-not-completely-at-random. Covariates, but not outcomes (MLR and HF hospitalizations 
during follow-up) were imputed using multiple imputation (“mice” package for R, m=10). Pooled 
results from the analyses performed on the 10 imputed datasets are shown in this paper, unless stated 
otherwise. Baseline characteristics were compared using t-tests for normally distributed continuous 
data, Kruskal-Wallis tests for non-normally distributed continuous data and chi-square tests for 
categorical data. HF markers (left ventricular ejection fraction [EF] and NTproBNP levels) were cross-
sectionally related to MLR in univariable and multivariable linear regression analyses. All available 
covariates were included: age, sex, diabetes, hypertension, hypercholesterolemia, BMI, smoking, 
indication for CAG, angiographic severity of CAD, treatment of CAD, history of acute coronary 
syndrome, PCI, CABG, CVA or PAD, kidney failure, medication use (ACE inhibitor, beta-blocker, 
statin, diuretic, P2Y12 inhibitor), NTproBNP levels (not for the NTproBNP analysis), EF (not for the 
EF analysis), troponin I levels and hsCRP levels.  
 Furthermore, the prediction of future HF hospitalizations by MLR was evaluated in 
multivariable Cox regression analysis (deceased patients were censored, n=115). For prediction, MLR 
was dichotomized into high MLR for all values in the upper quartile (>0.43) and low or normal MLR 
for the 3 lower quartiles (≤0.43). Covariates for the survival analyses were identical to those in the 
cross-sectional analysis. Because of the known influence of MI on monocyte and lymphocyte counts, 
we tested for interaction between indication for angiography and MLR in the analysis for outcome. 
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This interaction turned out to be significant and therefore stratified univariable analyses were 
performed for the indications for CAG. For MLR, we calculated integrated discrimination 
improvements (IDIs) and continuous net reclassification improvements (cNRIs) as described 
previously.6  
 Because of a positively skewed distribution, MLR, NTproBNP, TnI and hsCRP levels were 
log-transformed for analysis. All analyses were performed in the Rstudio environment for the R 
statistical programming software. Tests were two-tailed, a p-value <0.05 was deemed significant. 
 
Results 
 Table 1 summarizes baseline patient characteristics, stratified by low/normal and high MLR. 
Unstable angina and MI as compared to stable CAD were related to significantly higher MLR 
(analyzed as logMLR because of positive skewing) as shown in figure 1A. Univariably, a 1-point 
increase in logMLR resulted in an odds ratio (OR) of 1.13 [1.06-1.21], p<0.001 for unstable angina vs. 
stable CAD. Similarly, a 1-point increase in logMLR resulted in an OR of 1.10 [1.04-1.16], p<0.001 
for MI vs. stable CAD. In the multivariable model the OR for unstable angina vs. stable CAD was 
1.13 [1.05-1.21], p<0.001 and OR for MI vs. stable CAD 1.06 [0.99-1.13], p=0.08. In a univariable 
model, logMLR was significantly associated with the number of affected coronary arteries (OR=1.38 
[1.14-1.67], p<0.001, figure 1B), but this relation was inverted after multivariable adjustment 
(OR=0.78 [0.63-0.99], p=0.040).  
 LogMLR was also strongly related to EF in univariable analysis (OR=1.59 [95%CI 1.25-
2.02], p<0.001, figure 1C), indicating that a 1-point increase in logMLR gives 59% higher odds of 1-
category poorer EF (e.g. a deterioration from moderately impaired to poor EF). In multivariable 
analysis the significance of this relation was diminished (OR=1.07 [0.82-1.41], p=0.59). 
 In univariable analysis there was a strong relation between logMLR and logNTproBNP 
(β=0.78 [95% CI 0.59-0.97], p<0.001), indicating that for every 1-point increase in logMLR the 
logNTproBNP increased with 0.78 points (figure 1D). This relation remained statistically significant 
after adjustment for confounders (β=0.32 [0.13-0.51], p<0.001). There also was a significant 
correlation between hsCRP and MLR; Pearson’s r=0.24 (0.18-0.31), P<0.001. 
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 During a mean follow-up duration of 484 days, 46 HF hospitalizations occurred. Only 1 
patient experienced MI during follow-up and prior to HF hospitalization. For prediction, MLR was 
categorized in low/normal MLR and high MLR, as described above. Unadjusted for confounding 
factors, patients with a high MLR had an almost 4-fold higher risk of getting HF symptoms (hazard 
ratio [HR] 3.9 [2.2-7.0], p<0.001, figure 2). After adjustment for covariates, including EF, NTproBNP, 
Troponin I (TnI) and hsCRP, high MLR remained a significant predictor of HF hospitalizations (HR 
2.1 [1.1-4.1], p=0.039). Hazard ratios of these covariates are presented in supplementary table 1. 
 Moreover, IDI en cNRI for addition of MLR to the full HF prediction model proved to be 
significant, albeit of modest size. The IDI was 0.01 (95% confidence interval 0.00-0.06), p=0.05 and 
the cNRI was 0.32 (0.01-0.45), p<0.001. These data suggest that risk prediction would improve when 
MLR would be taken into account. The predictive value of high MLR far exceeded that of high 
monocyte counts (HR 0.5 [0.3-1.2], p=0.12) or low lymphocyte counts (HR 1.6 [0.8-3.1], p=0.2) 
alone, which were both non-significant in multivariable analysis.  
 There was a borderline significant interaction between high MLR and indication for CAG for 
the prediction of HF hospitalizations (pinteraction 0.065), suggesting that MLR would have slightly more 
prognostic value in stable/unstable angina than in MI patients (supplementary table 2). No interaction 
was found for sex (pinteraction=0.44) or EF (pinteraction=0.61), indicating that MLR could have similar 
prognostic value between men and women and in patients with preserved or reduced EF, respectively.  
 
Discussion 
 In CAD patients, MLR was strongly associated with NTproBNP levels and EF. Furthermore, 
high MLR showed predictive value on top of an extensive clinical risk prediction model for the 
prediction of HF hospitalizations after CAG. Our data show that MLR is closely related to HF 
parameters and future HF admissions in CAD patients. This is in line with preclinical studies showing 
that NFκB P50 in bone marrow-derived cells (and not in cardiomyocytes) determines adverse 
remodeling independent of infarct size.12 The current research connects to previous evidence on the 
predictive value of MLR in cardiovascular disease. In this regard, MLR relates to the severity of 
CAD13 and is a predictor of cardiovascular mortality.5,6 Moreover, MLR associates with adverse long-
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term outcomes in HF patients.14 These data indicate that MLR has predictive value not only in 
atherosclerosis, but also in the prediction of development of de novo HF and of adverse outcome in 
manifest HF. 
 Monocytes are key players in atherosclerosis and have been shown to predict cardiovascular 
and all-cause mortality in cardiovascular disease patients.5,15 Monocytes are also involved in adverse 
remodeling, which may result in HF.16 However, the role of monocytes is not restricted to detrimental 
effects.17 Several subtypes (classical, intermediate, non-classical) with specific functional properties 
have been identified and their role in HF remains relatively unexplored. Yet, intermediate monocytes 
have been shown to associate with the occurrence of cardiovascular events18, low EF19 and larger end-
diastolic left ventricular diameter.20 
 In addition, our data are in line with the previously described relation between lower 
lymphocyte numbers and poorer functional class in HF patients.21 The underlying biological 
mechanism remains largely unclear. The majority of the lymphocyte population consists of T-cells, 
further subdivided into T-helper cells (CD4+), cytotoxic T-cells (CD8+) and regulatory T-cells (Tregs), 
with a cell type-specific response to cardiovascular events. Of these, Tregs are of great importance for 
the modulation and suppression of inflammation, which is key in limiting the development and 
progression of cardiac damage after various stimuli.22 This is reflected by the observation that Treg 
numbers correlate with cardiac function and that both the number and suppressive capacity of Tregs is 
decreased in HF patients.23 In addition, several experimental studies have provided mechanistic 
evidence for the beneficial role of Tregs in hypertrophic remodeling and cardiac dysfunction after 
pressure-overload hypertrophy24 and MI.25 Data on T-cell subsets would therefore be of great interest. 
In contrast to T-cells, B-cells compose a small proportion of the total lymphocyte population and have 
been reported as causal players in atherosclerosis.26 Conflicting evidence with respect to their relation 
to cardiac remodeling27,28 emphasizes that our understanding of the role of B cells is still in its infancy. 
 After adjusting for hsCRP levels, MLR remained a significant predictor of future HF 
hospitalizations, suggesting that MLR provides information beyond systemic inflammation as 
reflected by hsCRP levels, mediated by IL6. Although hsCRP and IL6 levels are related to CAD 
severity and prognosis, these associations often disappear after appropriate statistical adjustment.29 
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 MLR is related to HF markers and HF hospitalizations during follow-up after CAG, 
independent of NTproBNP. Our results therefore suggest a potential role for MLR alongside or in lieu 
of NTproBNP. For example, cardiac resynchronization therapy can lower inflammatory markers in 
plasma.30 The response of MLR to HF therapy should be investigated as to evaluate its usability in 
therapy monitoring. The advantages of MLR are the ease of measurement and the low costs of 
measurement. While NTproBNP costs about €18 in the Netherlands, MLR can be measured for < €2, 
rendering it a cheap and attractive potential biomarker for risk stratification.  
 We acknowledge that our findings are limited to one cohort only; validation of our findings in 
an independent cohort is needed before considering clinical application. Ratios between specific 
monocyte and lymphocyte subsets, which were unavailable in our study, could further extend our 
understanding of the relation with HF indicators and improve prediction. Moreover, repeated MLR 
measurements in time would have been of immense value in order to better understand its role in HF 
progression. Also, data on the HF biomarkers galectin-3 and ST2 were not available in the current 
study, hindering direct comparison with MLR. 
 In conclusion, MLR related significantly to HF markers in CAD patients. Some of these 
associations remained significant after adjustment for amongst others EF, NTproBNP, TnI and hsCRP 
levels, suggesting an independent relation. Moreover, MLR had a significant and independent relation 
with HF hospitalizations during follow-up. 
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Figure 1. Relation of MLR with CAD and HF characteristics 
A: relation between MLR and indication for CAG. B: relation between MLR and severity of CAD. C: 
relation between MLR and left ventricular function. D: relation between MLR and NTproBNP levels 
(both on logarithmic scale). ^p-value results from univariable ordinal regression. *p-value results from 
univariable linear regression. CAD: coronary artery disease; CAG: coronary angiography; MLR: 
monocyte-to-lymphocyte ratio; VD: vessel disease 
 
Figure 2. Age- and sex-adjusted occurrence of HF hospitalization for high vs. low/normal MLR 
The occurrence of HF hospitalizations is shown stratified by MLR. Patients with a high MLR (upper 
quartile) had an almost 4-fold higher risk of getting HF symptoms (HR: 3.9 [2.2-7.0], p<0.001) 
compared to those with low or normal MLR values. After further adjustment for covariates, including 
EF, NTproBNP, Troponin I and hsCRP, high MLR remained a significant predictor of HF 
hospitalizations (see text). EF: ejection fraction; FU time; follow-up time; HF: heart failure; HR: 
hazard ratio; MLR: monocyte-to-lymphocyte ratio 
